Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQRS | ISIN: US92765F1084 | Ticker-Symbol: RYI
Tradegate
31.10.24
14:12 Uhr
0,190 Euro
+0,012
+6,74 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRACTA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRACTA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1700,19013:04
0,1740,18201.11.

Aktuelle News zur VIRACTA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.08.Viracta Therapeutics stock hits 52-week low at $0.277
18.08.Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out1.162LONDON (dpa-AFX) - This week, once again, companies across the biotech sector continued to re-evaluate their pipelines and trim their workforces in a bid to conserve cash and extend their financial...
► Artikel lesen
14.08.Viracta reports progress in PTCL treatment trial9
14.08.Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?5
14.08.Viracta lays off 23% of staff, pauses program to slim down for race to finish line in lymphoma4
14.08.Viracta Therapeutics Inc reports results for the quarter ended in June - Earnings Summary1
14.08.Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?3
14.08.Viracta jumps after corporate update4
14.08.Viracta Therapeutics GAAP EPS of -$0.25 beats by $0.111
14.08.Viracta Therapeutics, Inc. - 8-K, Current Report-
14.08.Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update159- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial...
► Artikel lesen
14.08.Viracta Therapeutics, Inc.: Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan82- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial...
► Artikel lesen
20.06.Viracta Therapeutics, Inc. - 8-K, Current Report3
31.05.Viracta Therapeutics, Inc. - 8-K, Current Report6
28.05.Ex-Jazz, Sunesis exec Swisher takes over at NodThera2
17.05.Viracta Therapeutics, Inc.: Viracta Therapeutics Announces New Employment Inducement Grants208SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
► Artikel lesen
14.05.Viracta Therapeutics Appoints Faerm As CFO1
09.05.Viracta Therapeutics GAAP EPS of -$0.233
09.05.Viracta Therapeutics, Inc. - 10-Q, Quarterly Report2
09.05.Viracta Therapeutics, Inc. - 8-K, Current Report1
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1